Compare FOR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | DBVT |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2007 | N/A |
| Metric | FOR | DBVT |
|---|---|---|
| Price | $30.31 | $20.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $31.75 | $31.75 |
| AVG Volume (30 Days) | 197.6K | ★ 477.4K |
| Earning Date | 01-20-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $1,685,000,000.00 | $5,502,000.00 |
| Revenue This Year | $0.52 | $1,768.71 |
| Revenue Next Year | $7.72 | $1,028.88 |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | ★ 15.89 | N/A |
| 52 Week Low | $18.00 | $3.82 |
| 52 Week High | $30.74 | $26.19 |
| Indicator | FOR | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 71.28 | 48.55 |
| Support Level | $29.13 | $20.25 |
| Resistance Level | $29.87 | $24.65 |
| Average True Range (ATR) | 0.95 | 1.54 |
| MACD | 0.32 | -0.30 |
| Stochastic Oscillator | 93.22 | 13.79 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.